Univest Securities, LLC Announces Closing of $12 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)
Key Highlights
- ➤China SXT Pharmaceuticals (SXTC) closed a $12 million registered direct offering.
- ➤Investors bought 8 million Class A shares or pre-funded warrants at $1.50.
- ➤China SXT issued 8 million immediately exercisable warrants at a $1.50 strike.
- ➤Warrants expire after one year and include a zero-cash exercise option.
- ➤Univest Securities acted as the offering’s sole placement agent.
Expert Statements
Edric Guo, Chief Executive Officer of Univest Securities, LLC
“Univest Securities, LLC”
New York, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the “Offering”) of $12 million for its client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), a China-based innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces.
Under the terms of the securities purchase agreement, the Company has agreed to sell to certain institutional investors an aggregate of 8,000,000 Class A ordinary shares of the Company, no par value per share (the "Shares") (or pre-funded warrants in lieu thereof), at a purchase price of $1.50 per share in the Offering.
Get started
Create a free account to read the full story.